Despite global efforts, food waste remains a challenging problem to solve. Each year, 1.3 billion tons of food is wasted due to poor handling, costing the global economy $1.5 trillion. This waste contributes 6-8% of annual greenhouse gas emissions and, what’s more, if saved, it could have fed about 1.26 billion people. No doubt, food
Read More
Blood cancer patients undergoing chemotherapy could soon have a reduced dependence on blood transfusions thanks to a new clinical study announced, run in partnership between biotech company Syntara (ASX: SNT), the University of Newcastle and the Australasian Leukaemia and Lymphoma Group (ALLG). The Phase 2 clinical study has been backed by a $0.83m grant to
Read More
Heads have turned in biotech circles with an ASX filing confirming that Platinum Asset Management has increased its stake in clinical-stage drug developer Syntara to 19.24%, fresh off the commencement of a Phase 2a clinical study that has the potential to become a new treatment for patients diagnosed with myelofibrosis (bone marrow cancer). The combination
Read More
Infectious diarrhea could soon be not so infectious with confirmation from biotech company Immuron (ASX: IMC) that the first patients have enrolled for their Phase 2 clinical trial seeking to address issues that arise from unpleasant episodes. The trial is a response to the persistent challenge of infectious diarrhea among travellers and military personnel deployed
Read More
Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with the first Australian patient in a Phase 2 clinical trial having been dosed with PXS-4708, a novel drug aimed at tackling Parkinson’s before its onset, along with other neurodegenerative disorders. The multi-national trial was initiated
Read More
In May 2023, diversified digital health company Vitura Health (ASX: VIT) announced a joint venture with Canadian psychedelic company PharmAla Biotech, giving birth to its Melbourne-based psychedelics arm, Cortexa. Providing an update on the 50-50 venture, the Company has noted an “Australian first” win. Its MDMA bulk GMP (good manufacturing practice) Active Pharmaceutical Ingredient (API)
Read More